We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare... read more Featured Products: More products

Download Mobile App




Cardiac Troponin Assay Compared with Existing Tests

By LabMedica International staff writers
Posted on 02 May 2017
Print article
Image: The Minicare I-20 system, for rapid diagnosis of a heart attack at the point of care (Photo courtesy of Philips Healthcare).
Image: The Minicare I-20 system, for rapid diagnosis of a heart attack at the point of care (Photo courtesy of Philips Healthcare).
Efficient rule-out of acute myocardial infarction (MI) in patients presenting with symptoms of cardiac ischemia facilitates early disposition of the patient to outpatient care, and helps to relieve the increasing crowding of the emergency departments (ED) in most hospitals.

Sensitive cardiac troponin (cTn) assays support such a decision based on results at admission and three hours after admission, according to current guidelines. The time needed for results to become available from the hospital central laboratory often delays the disposition decision for another one or two hours.

An international team of scientists collaborating with those at the University of Uppsala compared a novel point-of-care assay (POC) for cardiac troponin I with a high-sensitivity cardiac troponin I laboratory assay. They enrolled 450 prospectively patients admitted with suspected MI at EDs or coronary care units/chest pain units of seven hospitals in Germany, France, Austria and the Netherlands. Patients eligible for enrolment were adults (age ≥ 18 years) who had presented with symptoms suggestive of MI. Only patients who presented for the first time and less than 12 hours from onset of symptom onset were included.

The novel cTnI POC test, the Minicare cTnI, provides a cTnI result within 10 minutes. The test was compared with two widely used cTnI assays: the Abbott Architect hs-cTnI and the POC Abbott I-Stat cTnI. The concentrations of cTnT in lithium-heparin plasma were measured at the local hospital laboratories using a hs-cTnT assay.

The team observed significant correlations for cTnI concentrations measured on the Minicare cTnI, either as whole blood or plasma, compared with the Architect hs-cTnI and I-Stat cTnI. There was evidence of bias for both comparisons: 0.59 (whole blood) and 0.48 (plasma) for the Architect hs-cTnI and 0.48 (whole blood) and 0.43 (plasma) for the I-Stat cTnI. The 8% discordant results among MI patients between Minicare cTnI and Architect hs-cTnI were almost equally distributed with 3% showing elevated concentrations with Minicare cTnI and 5% showing elevated results with Architect hs-cTnI, but non-elevated results with the other.

The authors concluded that that the novel Minicare cTnI POC assay equals the clinical performance in their patient cohort of a hs-cTnI assay. The Minicare cTnI assay, with a very high negative predictive value, may become suitable for prompt and safe rule-out of MI for patients with symptoms suggestive of MI in the emergency setting using a 0/3 hour sampling protocol. The study was published online on March 25, 2017, in the journal Clinica Chimica Acta.

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.